Oxurion Postpones Strategic Transaction Due to Ongoing Discussions

Leuven-based biopharmaceutical company Oxurion has announced the postponement of the signing of a strategic transaction by four weeks. The decision follows ongoing discussions, prompted by the target's financial results exceeding expectations.

This transaction is crucial for Oxurion's strategic realignment and is a priority for all parties involved. Oxurion and its partners are determined to complete this agreement taking into account the revised financial context.

Oxurion reaffirms its commitment to completing this transaction and achieving its strategic objectives. Updates will be provided at each key stage of the process.